Authors' recommendations: According to studies, the first-line treatment of indolent follicular lymphoma with the BR combination is non-inferior or superior to the standard treatments R-CVP and R-CHOP in terms of progression-free survival. In patients who have recurrent disease, who have never received treatment that includes rituximab or who have achieved remission of at least 6 months duration following such treatment, the BR combination appears to be superior to FR and to bendamustine monotherapy. However, there are no data for evaluating the efficacy of this treatment in patients who have received BR as first-line therapy. Lastly, in patients with rituximab-refractory disease, bendamustine monotherapy is an effective treatment option.

Project Status: Completed

Year Published: 2015

URL for published report: https://www.inesss.qc.ca/en/publications/publications/publication/utilisation-de-la-bendamustine-pour-le-traitement-du-lymphome-folliculaire.html

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: Canada

Organisation Name: Institut national d'excellence en sante et en services sociaux

Contact Address: L'Institut national d'excellence en sante et en services sociaux (INESSS) , 2021, avenue Union, bureau 10.083, Montreal, Quebec, Canada, H3A 2S9;Tel: 1+514-873-2563, Fax: 1+514-873-1369

Contact Name: demande@inesss.qc.ca

Contact Email: demande@inesss.qc.ca

Copyright: L'Institut national d'excellence en sante et en services sociaux (INESSS)